Endocrine Abstracts

Vasoinhibin, historically also known as 16K PRL, is a peptide hormone with antiangiogenic, antivasodilatatory, and antivasopermeability effects generated by proteolytic cleavage of prolactin (PRL). The discovery of its role in diabetic retinopathy and peripartum cardiomyopathy led to the development of new pharmacological treatments and their evaluation in clinical interventional trials (ClinicalTrials.gov Identifier: NCT03161652 and NCT00998556). Recent insights into the func...